DK1673397T3 - Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer - Google Patents

Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer

Info

Publication number: DK1673397T3
Authority: DK; Denmark
Prior art keywords: cytotoxicity; kir2dl; evaluation; preparation; relates
Prior art date: 2003-07-02

Application number

DK04738967.1T

Other languages

English (en)

Inventor

Soeren Berg Padkjaer

Alessandro Moretta

Mariella Della Chiesa

Pascale Andre

Laurent Gauthier

Peter Andreas Nicolai Reumert Wagtmann

Original Assignee

Univ Genova

Innate Pharma

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-02

Filing date

2004-07-01

Publication date

2011-03-07

2004-07-01 Application filed by Univ Genova, Innate Pharma, Novo Nordisk As filed Critical Univ Genova

2011-03-07 Application granted granted Critical

2011-03-07 Publication of DK1673397T3 publication Critical patent/DK1673397T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Microbiology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

DK04738967.1T 2003-07-02 2004-07-01 Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer DK1673397T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48389403P	2003-07-02	2003-07-02
US54547104P	2004-02-19	2004-02-19
PCT/DK2004/000470 WO2005003168A2 (en)	2003-07-02	2004-07-01	Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies

Publications (1)

Publication Number	Publication Date
DK1673397T3 true DK1673397T3 (da)	2011-03-07

Family

ID=33567703

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04738967.1T DK1673397T3 (da)	2003-07-02	2004-07-01	Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
DK04744115.9T DK1639013T3 (da)	2003-07-02	2004-07-01	Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK04744115.9T DK1639013T3 (da)	2003-07-02	2004-07-01	Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi

Country Status (21)

Country	Link
US (2)	US9902936B2 (da)
EP (3)	EP1639013B1 (da)
JP (5)	JP4871125B2 (da)
KR (5)	KR20060079180A (da)
CN (2)	CN103467602B (da)
AT (1)	ATE490984T1 (da)
AU (2)	AU2004253770C1 (da)
BR (2)	BRPI0412138B8 (da)
CA (2)	CA2530272C (da)
CY (1)	CY1113394T1 (da)
DE (1)	DE602004030464D1 (da)
DK (2)	DK1673397T3 (da)
ES (2)	ES2725526T3 (da)
HR (1)	HRP20120845T1 (da)
IL (3)	IL172613A (da)
MX (1)	MXPA05013923A (da)
NO (4)	NO338818B1 (da)
PL (1)	PL1639013T3 (da)
PT (1)	PT1639013E (da)
RU (2)	RU2404993C2 (da)
WO (2)	WO2005003172A2 (da)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090191213A9 (en) *	2003-07-02	2009-07-30	Novo Nordisk A/S	Compositions and methods for regulating NK cell activity
EP2292264A3 (en)	2003-07-24	2012-12-19	Innate Pharma	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105849A1 (en) *	2004-04-30	2005-11-10	Innate Pharma	Compositions and methods for treating proliferative disorders such as nk-type ldgl
TWI422389B (zh) *	2004-07-01	2014-01-11	諾佛儂迪克股份有限公司	人類抗ｋｉｒ抗體
AU2005259221B2 (en)	2004-07-01	2011-02-10	Innate Pharma	Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
ES2925912T3 (es)	2004-07-10	2022-10-20	The Institute For Cancer Res	Líneas de células asesinas naturales humanas genéticamente modificadas
AU2005302291B2 (en) *	2004-11-02	2011-02-10	The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services	Compositions and methods for treating hyperproliferative disorders
US8551483B2 (en)	2005-01-06	2013-10-08	Innate Pharma S.A.S.	Methods of treating viral infections by administering KIR2DL-binding antibodies
ES2732623T3 (es)	2005-01-06	2019-11-25	Innate Pharma Sa	Tratamientos y métodos de combinación anti-KIR
ES2374603T3 (es)	2005-01-06	2012-02-20	Novo Nordisk A/S	Agentes de unión a kir y procedimientos de uso de los mismos.
GT200600148A (es) *	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
EP2322557B1 (en)	2005-10-14	2017-08-30	Innate Pharma	Compositions and methods for treating proliferative disorders
CN105037549B (zh) *	2007-01-11	2018-09-28	诺和诺德公司	抗-kir抗体、制剂及其应用
WO2010065939A1 (en)	2008-12-05	2010-06-10	Indiana University Research & Technology Corporation	Combination therapy to enhace nk cell mediated cytotoxicty
EP2808402A3 (en) *	2008-12-29	2015-03-25	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Methods of predicting responsiveness to interferon treatment
JP5766619B2 (ja) *	2010-02-08	2015-08-19	株式会社日本バイオセラピー研究所	Ｎｋ細胞強化型血液製剤の製造方法
JP6224457B2 (ja)	2010-11-22	2017-11-01	イネイト・ファルマ・ソシエテ・アノニム	Ｎｋ細胞調節治療及び悪性血液疾患の治療方法
CA2837184C (en)	2011-05-25	2021-09-21	Innate Pharma, S.A.	Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2012175613A1 (en)	2011-06-21	2012-12-27	Innate Pharma	NKp46-MEDIATED NK CELL TUNING
JO3370B1 (ar) *	2011-11-10	2019-03-13	Regeneron Pharma	طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP2782931B1 (en) *	2011-11-23	2016-12-14	F. Hoffmann-La Roche AG	Cd40l expressing mammalian cells and their use
RU2682449C2 (ru) *	2012-09-19	2019-03-19	Иннейт Фарма	Связывающие kir3dl2 агенты
PT2904011T (pt)	2012-10-02	2017-10-27	Bristol Myers Squibb Co	Combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar cancro
US10494433B2 (en)	2013-11-06	2019-12-03	Bristol-Myers Squibb Company	Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
JP6654781B2 (ja) *	2014-08-29	2020-02-26	国立大学法人北海道大学	Ｋｉｒ２ｄｓ１に対するモノクローナル抗体
EP3212227B1 (en)	2014-10-28	2020-01-15	Children's University Hospital Tübingen	Treatment of pediatric bcp-all patients with an anti-kir antibody
KR20250022235A (ko)	2015-02-06	2025-02-14	내셔널 유니버시티 오브 싱가포르	치료적 면역 세포의 효능의 향상 방법
HUE050894T2 (hu)	2015-04-17	2021-01-28	Bristol Myers Squibb Co	Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját
CN114099712A (zh)	2015-05-06	2022-03-01	斯尼普技术有限公司	改变微生物种群和改善微生物群
AU2016263808B2 (en)	2015-05-21	2019-01-03	Harpoon Therapeutics, Inc.	Trispecific binding proteins and methods of use
US10682390B2 (en)	2015-07-16	2020-06-16	Biokine Therapeutics Ltd.	Compositions and methods for treating cancer
JP2019500893A (ja)	2015-11-03	2019-01-17	ヤンセンバイオテツク，インコーポレーテツド	Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
EP3371221A2 (en)	2015-11-07	2018-09-12	MultiVir Inc.	Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SI3458053T1 (sl)	2016-05-20	2022-04-29	Biohaven Therapeutics Ltd.	Uporaba riluzola, predzdravil riluzola ali analogov riluzola z imunoterapijami za zdravljenje rakov
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
GB201609811D0 (en)	2016-06-05	2016-07-20	Snipr Technologies Ltd	Methods, cells, systems, arrays, RNA and kits
US20190233534A1 (en)	2016-07-14	2019-08-01	Fred Hutchinson Cancer Research Center	Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
BR112019006041A2 (pt)	2016-09-27	2019-09-03	Board Of Regents, The University Of Texas System	métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
GB201616365D0 (en) *	2016-09-27	2016-11-09	Helsingin Yliopisto	Non-genetic modification of enveloped viruses
CN110072540B (zh)	2016-10-12	2023-06-02	得克萨斯州大学系统董事会	用于tusc2免疫治疗的方法和组合物
WO2018073363A1 (en)	2016-10-21	2018-04-26	Innate Pharma	Treatment with anti-kir3dl2 agents
WO2018111902A1 (en)	2016-12-12	2018-06-21	Multivir Inc.	Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
MX2019010958A (es)	2017-03-31	2019-10-17	Bristol Myers Squibb Co	Metodos de tratamiento de tumores.
CN110573529A (zh)	2017-04-05	2019-12-13	韩国生命工学研究院	激活nk细胞的融合蛋白、nk细胞和包含其的药物组合物
CN110891974B (zh)	2017-05-12	2021-08-06	哈普恩治疗公司	间皮素结合蛋白质
WO2018218207A1 (en)	2017-05-26	2018-11-29	Fred Hutchinson Cancer Research Center	Anti-cd33 antibodies and uses thereof
CN107261304A (zh) *	2017-06-05	2017-10-20	中国兽医药品监察所	一种奶牛的布鲁氏菌病免疫试剂盒及其应用
US11648269B2 (en)	2017-08-10	2023-05-16	National University Of Singapore	T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
CR20200196A (es)	2017-10-13	2020-06-05	Harpoon Therapeutics Inc	Proteínas trispecìficas y mètodos de uso
KR20200064132A (ko)	2017-10-15	2020-06-05	브리스톨-마이어스 스큅 컴퍼니	종양을 치료하는 방법
CN108060137B (zh) *	2017-12-26	2021-07-02	博生吉医药科技(苏州)有限公司	Il7和il21修饰的nk92细胞、制备方法及其应用
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200118824A (ko)	2018-02-08	2020-10-16	드래곤플라이 쎄라퓨틱스, 인크.	자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
US11884733B2 (en)	2018-02-08	2024-01-30	Dragonfly Therapeutics, Inc.	Antibody variable domains targeting the NKG2D receptor
JP7353576B2 (ja)	2018-02-20	2023-10-02	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
CN112020510B (zh)	2018-03-19	2024-10-11	茂体外尔公司	包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
US10760075B2 (en)	2018-04-30	2020-09-01	Snipr Biome Aps	Treating and preventing microbial infections
DE112019001543T5 (de)	2018-03-25	2020-12-17	Snipr Biome Aps.	Behandlung und verhinderung von mikrobiellen infektionen
JP2021519771A (ja)	2018-03-30	2021-08-12	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	腫瘍を処置する方法
EP3784776A4 (en)	2018-05-23	2022-01-26	National University of Singapore	Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53284A (fr)	2018-08-08	2022-01-26	Dragonfly Therapeutics Inc	Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
WO2020033630A1 (en)	2018-08-08	2020-02-13	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3849565A4 (en)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
WO2020069028A1 (en)	2018-09-25	2020-04-02	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
JP7450622B2 (ja)	2018-12-21	2024-03-15	ヴァレリオ・セラピューティクス	新規のコンジュゲートされた核酸分子及びその使用
CN114174538A (zh)	2019-05-30	2022-03-11	百时美施贵宝公司	适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114127315A (zh)	2019-05-30	2022-03-01	百时美施贵宝公司	鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
US20220233691A1 (en)	2019-05-30	2022-07-28	Bristol-Myers Squibb Company	Cell localization signature and combination therapy
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN111424012A (zh) *	2020-03-30	2020-07-17	威海市中心医院	一种nk细胞培养用的饲养细胞去增殖能力的处理方法
AR122018A1 (es)	2020-05-06	2022-08-03	Dragonfly Therapeutics Inc	Proteínas que se unen a nkg2d, cd16 y clec12a
AR122644A1 (es)	2020-06-19	2022-09-28	Onxeo	Nuevas moléculas de ácido nucleico conjugado y sus usos
JP2023532768A (ja)	2020-07-07	2023-07-31	バイオエヌテックエスエー	Ｈｐｖ陽性癌の治療用ｒｎａ
MX2023002326A (es)	2020-08-31	2023-03-21	Bristol Myers Squibb Co	Firma de localizacion celular e inmunoterapia.
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022140755A1 (en) *	2020-12-23	2022-06-30	H. Lee Moffitt Cancer Center And Research Institute Inc.	Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
HRP20250628T1 (hr)	2020-12-28	2025-07-18	Bristol-Myers Squibb Company	Mješavine antitijela i postupci njihove upotrebe
MX2023007650A (es)	2020-12-28	2023-09-11	Bristol Myers Squibb Co	Metodos de tratamiento de tumores.
MX2023009100A (es)	2021-02-03	2023-09-25	Mozart Therapeutics Inc	Agentes aglutinantes y métodos para usar los mismos.
WO2022187539A1 (en)	2021-03-03	2022-09-09	Dragonfly Therapeutics, Inc.	Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
JP2024525758A (ja)	2021-07-13	2024-07-12	ビオンテック・ソシエタス・エウロパエア	がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
EP4412814A1 (en)	2021-10-08	2024-08-14	3M Innovative Properties Company	Slot die assembly with tuned stiffness, reduced draw zone, and force budget
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
WO2023110937A1 (en)	2021-12-14	2023-06-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP2025500922A (ja)	2021-12-16	2025-01-15	ヴァレリオ・セラピューティクス	新規のコンジュゲートされた核酸分子及びその使用
WO2023178329A1 (en)	2022-03-18	2023-09-21	Bristol-Myers Squibb Company	Methods of isolating polypeptides
EP4531916A1 (en)	2022-06-02	2025-04-09	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
GB202209518D0 (en)	2022-06-29	2022-08-10	Snipr Biome Aps	Treating & preventing E coli infections
WO2024026385A1 (en) *	2022-07-28	2024-02-01	H. Lee Moffitt Cancer Center And Research Institute Inc.	Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
TW202426486A (zh) *	2022-10-25	2024-07-01	日商第一三共股份有限公司	使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
WO2024126457A1 (en)	2022-12-14	2024-06-20	Astellas Pharma Europe Bv	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh)	2023-12-08	2025-11-01	日商安斯泰來製藥公司	含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
US20250215087A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg depleting agent
CN117883553B (zh) *	2024-01-12	2024-08-27	成都医学院	Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5660827A (en) *	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US5539094A (en)	1993-11-12	1996-07-23	La Jolla Cancer Research Foundation	DNA encoding Bcl-2-associated proteins
IL108501A (en) *	1994-01-31	1998-10-30	Mor Research Applic Ltd	Antibodies and pharmaceutical compositions containing them
US5583034A (en) *	1994-02-22	1996-12-10	La Jolla Institute For Allergy And Immunology	Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) *	1994-05-24	1998-09-15	The United States Of America As Represented By The Department Of Health And Human Services	Molecular clone of a P58 receptor protein and uses thereof
NZ298145A (en)	1994-12-29	1998-08-26	Yamanouchi Pharma Co Ltd	Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US6750044B1 (en)	1996-10-17	2004-06-15	Genentech, Inc.	Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO2000026671A1 (de) *	1998-10-29	2000-05-11	Connex Gmbh	Nachweis von säure-resistenten mikroorganismen im stuhl
US6342219B1 (en) *	1999-04-28	2002-01-29	Board Of Regents, The University Of Texas System	Antibody compositions for selectively inhibiting VEGF
KR100419555B1 (ko) *	2000-05-29	2004-02-19	주식회사유한양행	비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
EP2292264A3 (en) *	2003-07-24	2012-12-19	Innate Pharma	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
AU2005259221B2 (en) *	2004-07-01	2011-02-10	Innate Pharma	Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US8993319B2 (en) *	2004-12-28	2015-03-31	Innate Pharma S.A.	Monoclonal antibodies against NKG2A
ES2374603T3 (es) *	2005-01-06	2012-02-20	Novo Nordisk A/S	Agentes de unión a kir y procedimientos de uso de los mismos.
ES2732623T3 (es) *	2005-01-06	2019-11-25	Innate Pharma Sa	Tratamientos y métodos de combinación anti-KIR
US8551483B2 (en) *	2005-01-06	2013-10-08	Innate Pharma S.A.S.	Methods of treating viral infections by administering KIR2DL-binding antibodies
EP2322557B1 (en) *	2005-10-14	2017-08-30	Innate Pharma	Compositions and methods for treating proliferative disorders
CN105037549B (zh)	2007-01-11	2018-09-28	诺和诺德公司	抗-kir抗体、制剂及其应用
CA2837184C (en) *	2011-05-25	2021-09-21	Innate Pharma, S.A.	Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2014066532A1 (en) *	2012-10-23	2014-05-01	Bristol-Myers Squibb Company	Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
US10494433B2 (en) *	2013-11-06	2019-12-03	Bristol-Myers Squibb Company	Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
US9884593B2 (en) *	2015-02-12	2018-02-06	Pro-Gard Products, Llc	Weapon mounting system

2004
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es not_active Expired - Lifetime
- 2004-07-01 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en not_active Ceased
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt not_active IP Right Cessation
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en not_active Expired - Lifetime
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko not_active Ceased
- 2004-07-01 US US10/563,045 patent/US9902936B2/en active Active
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh not_active Expired - Lifetime
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 CA CA2530272A patent/CA2530272C/en not_active Expired - Lifetime
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es not_active Expired - Lifetime
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en not_active Ceased
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko not_active Expired - Lifetime
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en not_active Expired - Lifetime
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en not_active Expired
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en not_active Expired - Lifetime
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en not_active Expired
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko not_active Expired - Lifetime
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh not_active Expired - Lifetime
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko not_active Expired - Lifetime
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja not_active Expired - Lifetime
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja not_active Expired - Lifetime
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt not_active IP Right Cessation
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de not_active Expired - Lifetime
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko not_active Expired - Lifetime
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja not_active Expired - Lifetime
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja not_active Expired - Lifetime
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending

Also Published As

Publication number	Publication date
IL172700A0 (en)	2006-04-10
EP1673397A2 (en)	2006-06-28
PT1639013E (pt)	2012-12-03
US20180216069A1 (en)	2018-08-02
US9902936B2 (en)	2018-02-27
JP5826697B2 (ja)	2015-12-02
HK1091662A1 (en)	2007-01-26
ES2725526T3 (es)	2019-09-24
ATE490984T1 (de)	2010-12-15
RU2404993C2 (ru)	2010-11-27
IL238490A0 (en)	2015-06-30
KR20120059659A (ko)	2012-06-08
KR20060111440A (ko)	2006-10-27
NO20056048L (no)	2006-04-03
NO338255B1 (no)	2016-08-08
NO20060528L (no)	2006-02-01
IL172613A (en)	2010-12-30
JP4871125B2 (ja)	2012-02-08
CA2530272A1 (en)	2005-01-13
CN103588880B (zh)	2019-09-17
CN103467602B (zh)	2018-04-10
AU2004253770B2 (en)	2009-10-29
WO2005003168A3 (en)	2005-05-06
CN103588880A (zh)	2014-02-19
KR101375153B1 (ko)	2014-03-18
JP2008500947A (ja)	2008-01-17
KR20060079180A (ko)	2006-07-05
AU2004253630B2 (en)	2010-11-25
AU2004253770C1 (en)	2010-04-15
KR101325023B1 (ko)	2013-11-04
NO20160411A1 (no)	2016-03-10
RU2376315C2 (ru)	2009-12-20
NO20160264A1 (no)	2016-02-16
EP2289939A2 (en)	2011-03-02
DE602004030464D1 (de)	2011-01-20
NO338818B1 (no)	2016-10-24
US11365393B2 (en)	2022-06-21
BRPI0412138A (pt)	2006-08-15
CY1113394T1 (el)	2016-06-22
MXPA05013923A (es)	2006-08-11
EP1673397B1 (en)	2010-12-08
WO2005003172A2 (en)	2005-01-13
NO342318B1 (no)	2018-05-07
JP2007524612A (ja)	2007-08-30
KR20120024998A (ko)	2012-03-14
BRPI0412138B1 (pt)	2021-01-26
JP2015163068A (ja)	2015-09-10
NO343342B1 (no)	2019-02-04
AU2004253630A1 (en)	2005-01-13
JP2012176953A (ja)	2012-09-13
KR101420344B1 (ko)	2014-07-16
EP2289939B1 (en)	2019-03-27
JP2018153185A (ja)	2018-10-04
WO2005003172A3 (en)	2005-03-10
US20060263361A1 (en)	2006-11-23
EP1639013B1 (en)	2012-09-12
EP2289939A3 (en)	2013-12-04
CA2530272C (en)	2018-05-01
BRPI0412153A (pt)	2006-08-22
WO2005003168A2 (en)	2005-01-13
RU2006102960A (ru)	2006-06-27
KR101444717B1 (ko)	2014-09-26
CA2530591A1 (en)	2005-01-13
RU2005140152A (ru)	2007-08-27
AU2004253770A1 (en)	2005-01-13
PL1639013T3 (pl)	2013-02-28
BRPI0412138B8 (pt)	2021-05-25
HRP20120845T1 (hr)	2012-11-30
ES2393485T3 (es)	2012-12-21
BRPI0412153B8 (pt)	2021-05-25
JP6556465B2 (ja)	2019-08-07
CN103467602A (zh)	2013-12-25
JP5015592B2 (ja)	2012-08-29
EP1639013A2 (en)	2006-03-29
IL172700A (en)	2015-05-31
IL172613A0 (en)	2006-04-10
KR20130062379A (ko)	2013-06-12
BRPI0412153B1 (pt)	2019-07-30
DK1639013T3 (da)	2013-01-07

Publication	Publication Date	Title
DK1673397T3 (da)	2011-03-07	Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
EP2287195A3 (en)	2013-12-04	Pan-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
CA2492096A1 (en)	2004-01-22	Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
MY141215A (en)	2010-03-31	Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, method and uses
WO2005063820A3 (en)	2006-03-09	Il-7 fusion proteins
ATE387435T1 (de)	2008-03-15	Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
WO2005042029A3 (en)	2005-12-22	Psma formulations and uses thereof
DK1436381T3 (da)	2005-09-19	Dedifferentierede, programmerbare stamceller af monocytisk oprindelse og deres fremstilling og anvendelse
WO2006085961A3 (en)	2006-12-14	Anti-mcp-1 antibodies, compositions, methods and uses
NO20045521L (no)	2004-12-17	Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
UA116614C2 (uk)	2018-04-25	Антитіло до фактора d і його застосування
DE60327745D1 (de)	2009-07-09	Verwendung von adapalen zur behandlung dermatologischer erkrankungen
WO2004043361A3 (en)	2007-10-04	Compositions and methods for the treatment of natural killer cell related diseases
NO20081124L (no)	2008-05-22	Anti-CD 3 antistoff-formuleringer
NO20090348L (no)	2009-04-24	Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
DE60320009D1 (de)	2008-05-08	Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
WO2006116181A3 (en)	2007-01-18	Regulatory t cell mediator proteins and uses thereof
DK1240326T3 (da)	2009-06-02	Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
TW200716174A (en)	2007-05-01	Anti-MCP-1 antibodies, compositions, methods and uses
ATE413167T1 (de)	2008-11-15	Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
WO2006002102A3 (en)	2006-05-04	Spirocyclic compounds useful as modulators of nuclear hormone receptor function
ATE363890T1 (de)	2007-06-15	Kationische polymerisate und deren verwendung in kosmetischen formulierungen
AU2003259750A8 (en)	2004-03-03	Methods and compositions for targeting secretory lysosomes
MX2007000210A (es)	2007-08-02	Anticuerpos que se unen a los receptores kir2dl1,-2,3 pero no a kir2ds4 y su uso terapeutico.
BRPI0410252A (pt)	2006-05-16	materiais de revestimento de um componente termicamente curáveis, sua preparação e uso